RA Capital Management

CellCentric is a biotechnology company that develops p300/CBP inhibitors to treat cancer and multiple myeloma.

Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders.

Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.

Imbria Pharmaceuticals is a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases.

Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.

Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway.

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.